RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ascendis Pharma A/S Stock

Ascendis Pharma A/S EBIT 2024

Ascendis Pharma A/S EBIT

-202.33 M EUR

Ticker

ASND

ISIN

US04351P1012

WKN

A14M6X

In 2024, Ascendis Pharma A/S's EBIT was -202.33 M EUR, a -54.81% increase from the -447.71 M EUR EBIT recorded in the previous year.

The Ascendis Pharma A/S EBIT history

YEAREBIT (undefined EUR)
2030e2.42
2029e1.21
2028e1.34
2027e0.86
2026e0.26
2025e-0.01
2024e-0.2
2023-0.45
2022-0.56
2021-0.45
2020-0.33
2019-0.23
2018-0.15
2017-0.11
2016-0.07
2015-0.04
2014-0.01
20130.01
20120

Ascendis Pharma A/S Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ascendis Pharma A/S, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ascendis Pharma A/S from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ascendis Pharma A/S’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ascendis Pharma A/S. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ascendis Pharma A/S’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ascendis Pharma A/S’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ascendis Pharma A/S’s growth potential.

Ascendis Pharma A/S Revenue, EBIT and net profit per share

DateAscendis Pharma A/S RevenueAscendis Pharma A/S EBITAscendis Pharma A/S Net Income
2030e4.26 B undefined2.42 B undefined2.53 B undefined
2029e3.19 B undefined1.21 B undefined1.83 B undefined
2028e2.52 B undefined1.34 B undefined1.35 B undefined
2027e1.91 B undefined864.98 M undefined912.36 M undefined
2026e1.2 B undefined259.94 M undefined187.91 M undefined
2025e732.31 M undefined-9.12 M undefined-68.24 M undefined
2024e447.92 M undefined-202.33 M undefined-311.78 M undefined
2023266.72 M undefined-447.71 M undefined-481.45 M undefined
202251.17 M undefined-561.81 M undefined-583.19 M undefined
20217.78 M undefined-451.79 M undefined-383.58 M undefined
20206.95 M undefined-330.62 M undefined-418.96 M undefined
201913.38 M undefined-226.72 M undefined-218.02 M undefined
201810.58 M undefined-154.76 M undefined-130.1 M undefined
20171.53 M undefined-111.54 M undefined-123.9 M undefined
20164.61 M undefined-72.92 M undefined-68.51 M undefined
20158.12 M undefined-41.83 M undefined-32.92 M undefined
201413.98 M undefined-11.99 M undefined-9.66 M undefined
201320.41 M undefined5.28 M undefined4.08 M undefined
201215.58 M undefined1.51 M undefined1.25 M undefined

Ascendis Pharma A/S stock margins

The Ascendis Pharma A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ascendis Pharma A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ascendis Pharma A/S.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ascendis Pharma A/S's sales revenue. A higher gross margin percentage indicates that the Ascendis Pharma A/S retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ascendis Pharma A/S's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ascendis Pharma A/S's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ascendis Pharma A/S's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ascendis Pharma A/S. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ascendis Pharma A/S's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ascendis Pharma A/S Margin History

Ascendis Pharma A/S Gross marginAscendis Pharma A/S Profit marginAscendis Pharma A/S EBIT marginAscendis Pharma A/S Profit margin
2030e83.36 %56.78 %59.34 %
2029e83.36 %38.02 %57.24 %
2028e83.36 %53.15 %53.58 %
2027e83.36 %45.22 %47.69 %
2026e83.36 %21.63 %15.63 %
2025e83.36 %-1.25 %-9.32 %
2024e83.36 %-45.17 %-69.61 %
202383.36 %-167.86 %-180.51 %
202276.29 %-1,097.93 %-1,139.71 %
202154.76 %-5,807.07 %-4,930.33 %
202083.36 %-4,757.12 %-6,028.2 %
201983.36 %-1,694.47 %-1,629.45 %
201883.36 %-1,462.76 %-1,229.68 %
201783.36 %-7,290.2 %-8,098.04 %
201683.36 %-1,581.78 %-1,486.12 %
201583.36 %-515.15 %-405.42 %
201483.36 %-85.77 %-69.1 %
201383.36 %25.87 %19.99 %
201283.36 %9.69 %8.02 %

Ascendis Pharma A/S Aktienanalyse

What does Ascendis Pharma A/S do?

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark that focuses on developing innovative therapies for diseases that currently have no suitable treatment options. The company was founded in 2007 and is headquartered in Hellerup, Denmark. History The company was founded by an experienced team of researchers and professionals from the pharmaceutical and biotech industry who recognized the need for new therapies for chronic diseases. They used innovative technologies to develop drugs that would have longer-lasting effects, thus reducing the need for frequent doses. In 2015, the company went public to raise additional capital for the further development of their technologies and products. Business model Ascendis Pharma A/S is working on the development of drugs using a proprietary technology platform called TransCon technology. TransCon technology is a novel delivery system that allows drugs to remain in the body for longer periods of time, thus achieving a continuous effect. This leads to a reduced need for frequent doses, improving patient care and adherence to therapy. The company follows an asset-based business model strategy. It aims to market its products globally through a licensing and partnering approach. By partnering with established pharmaceutical companies, Ascendis Pharma A/S can introduce their drugs into broader markets while ensuring resources for further research and development. Divisions Ascendis Pharma A/S has two main business divisions: 1. Endocrinology: Ascendis Pharma A/S is a leader in the development of therapies for diseases caused by hormonal disorders. The TransCon technology is used for the delivery of hormones such as growth hormone, parathyroid hormone, follicle-stimulating hormone, and luteinizing hormone to achieve continuous release in the body. 2. Oncology: The company also utilizes the TransCon technology for the delivery of cytokines for cancer immunotherapy. Products The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone, a growth hormone therapy that has longer-lasting effects and only needs to be administered once a week for children with growth hormone deficiency. The company also has TransCon PTH and TransCon CNP in the endocrinology pipeline. In oncology, the company has developed TransCon IL-2, an interleukin-2 immunotherapy for cancer. Summary Ascendis Pharma A/S is an innovative biopharmaceutical company specializing in the development of therapies for chronic diseases. The company utilizes its proprietary technology platform, TransCon technology, to develop drugs that have longer-lasting effects and reduce the need for frequent doses. It focuses on endocrinology and oncology and follows an asset-based business model strategy by entering partnerships with established pharmaceutical companies. The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone. Ascendis Pharma A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Ascendis Pharma A/S's EBIT

Ascendis Pharma A/S's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Ascendis Pharma A/S's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Ascendis Pharma A/S's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Ascendis Pharma A/S’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Ascendis Pharma A/S stock

How much did Ascendis Pharma A/S achieve in EBIT for the current year?

In the current year, Ascendis Pharma A/S has achieved an EBIT of -202.33 M EUR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Ascendis Pharma A/S.

How has the EBIT of Ascendis Pharma A/S developed in recent years?

The EBIT of Ascendis Pharma A/S has increased by -54.808% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Ascendis Pharma A/S?

The EBIT of Ascendis Pharma A/S is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Ascendis Pharma A/S pay?

Over the past 12 months, Ascendis Pharma A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ascendis Pharma A/S is expected to pay a dividend of 0 EUR.

What is the dividend yield of Ascendis Pharma A/S?

The current dividend yield of Ascendis Pharma A/S is .

When does Ascendis Pharma A/S pay dividends?

Ascendis Pharma A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ascendis Pharma A/S?

Ascendis Pharma A/S paid dividends every year for the past 0 years.

What is the dividend of Ascendis Pharma A/S?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ascendis Pharma A/S located?

Ascendis Pharma A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ascendis Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ascendis Pharma A/S from 7/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/26/2024.

When did Ascendis Pharma A/S pay the last dividend?

The last dividend was paid out on 7/26/2024.

What was the dividend of Ascendis Pharma A/S in the year 2023?

In the year 2023, Ascendis Pharma A/S distributed 0 EUR as dividends.

In which currency does Ascendis Pharma A/S pay out the dividend?

The dividends of Ascendis Pharma A/S are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Ascendis Pharma A/S stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Ascendis Pharma A/S

Our stock analysis for Ascendis Pharma A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ascendis Pharma A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.